Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Empagliflozin in NODAT
NCT03642184 · RenJi Hospital · PHASE4 · terminated · last registry update 2023-11-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Difficult in enrolling suitable participants” | – | Registry record, RenJi Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC5A2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-11-06Phase 3 first posted: AstraZeneca, Baxdrostat and dapagliflozin (NCT06677060)
- 2024-10-22Phase 3 first posted: Insel Gruppe AG, University Hospital Bern, Empagliflozin 10 MG + Placebo (NCT06653738)
- 2024-10-18Phase 3 first posted: THPharm Corp., THP-00101 + THP-00102 (NCT06647745)
- 2024-09-19Phase 3 first posted: Shandong Suncadia Medicine Co., Ltd., HRS-7535 tablet + dapagliflozin tablet (NCT06589765)
- 2024-08-26Phase 3 first posted: Celltrion, CT-L03 Group 1 + CT-L03 Group 2 (NCT06571591)
- 2024-08-19Phase 3 first posted: Eurofarma Laboratorios S.A., N0892 + Januvia® + Glifage XR® + Placebo (NCT06560333)
- 2024-08-01Phase 3 first posted: Boehringer Ingelheim, BI 690517 + Placebo matching BI 690517 (NCT06531824)
- 2024-07-17Phase 3 first posted: University of Missouri-Columbia, Empagliflozin 10 MG + Placebo (NCT06506422)
- 2024-07-15Results posted on the registry: Tanabe Pharma Corporation, Canagliflozin + Placebo (NCT03436693)
- 2024-07-03Results posted on the registry: Travere Therapeutics, Inc., sparsentan + irbesartan (NCT03762850)
- 2024-06-21Phase 3 first posted: University of East Anglia, Empagliflozin 10 MG (NCT06469645)
- 2024-05-22Phase 3 first posted: Boehringer Ingelheim, vicadrostat + empagliflozin (NCT06424288)
- 2024-05-16Phase 3 first posted: Shenzhen HighTide Biopharmaceutical Ltd., HTD1801 + Dapagliflozin (NCT06415773)
- 2024-05-08Phase 3 first posted: Beni-Suef University, Metformin + Dapagliflozin (NCT06405178)
- 2024-03-19Phase 3 first posted: Kirby Institute, Dapagliflozin 10mg Tab + Pitavastatin 4 Mg Oral Tablet (NCT06317051)
- 2024-03-13Phase 3 first posted: AstraZeneca, balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg + balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg (NCT06307652)
- 2024-02-20Phase 3 first posted: AstraZeneca, Baxdrostat/dapagliflozin + Dapagliflozin in combination with placebo (NCT06268873)
- 2024-01-05Phase 3 first posted: Eli Lilly and Company, Orforglipron + Dapagliflozin (NCT06192108)
- 2023-12-18Phase 3 first posted: Ottawa Heart Institute Research Corporation, Dapagliflozin 10mg Tab (NCT06174753)
- 2023-11-29Phase 3 first posted: University of Minnesota, Empagliflozin (NCT06149793)
- 2023-11-03Phase 3 first posted: Sohag University, SGLT2 inhibitor (NCT06117137)
- 2023-10-18Phase 3 first posted: AstraZeneca, Zibotentan/Dapagliflozin + Dapagliflozin (NCT06087835)
- 2023-09-11Phase 3 first posted: Chulalongkorn University, Empagliflozin 10 MG + Placebo (NCT06030843)
- 2023-09-06Phase 3 first posted: Colorado Prevention Center, Finerenone + Empagliflozin (NCT06024746)
- 2023-08-14Phase 3 first posted: Mostafa Bahaa, Mesalamine + Dapagliflozin 10mg Tab (NCT05986136)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision